REVIEW: CLINICAL AND SYSTEMATIC REVIEWSOpioid-Induced Constipation: Challenges and Therapeutic OpportunitiesCamilleri, Michael MD1Author Information 1Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Rochester, Minnesota, USA Correspondence: Michael Camilleri, MD, Clinical Enteric Neuroscience Translational and Epidemiological Research, Mayo Clinic, Charlton 8-110, 200 First St SW, Rochester, Minnesota 55905, USA. E-mail: [email protected] If you wish to receive credit for this activity, please refer to the Web site:http://www.acg.gi.org/acgjournalcme/. Article Title: Opioid-Induced Constipation: Challenges and Therapeutic Opportunities published online 22 February 2011 Received 22 December 2010; accepted 17 January 2011 American Journal of Gastroenterology: May 2011 - Volume 106 - Issue 5 - p 835-842 doi: 10.1038/ajg.2011.30 Buy Take the CME Test Metrics Abstract There has been an alarming increase in the prescription of opiates and opioids for chronic non-cancer pain in the past 15 years. It is estimated that opiate-induced constipation (OIC) is experienced by ∼40% of these patients, and that constipation and other gastrointestinal symptoms may dissuade patients from using the required analgesic dose to achieve effective pain relief. Opiates have several effects on gastrointestinal functions, and the inhibition of colonic transit and intestinal and colonic secretion results in constipation. Several different pharmacological approaches are being developed to prevent or treat OIC: prolonged release formulations that contain naloxone (a less specific opiate antagonist that is widely distributed) and a new class of peripherally restricted μ-opiate receptor antagonists, including methylnaltrexone, alvimopan, tapentadol, NKTR-118, and TD-1211. Novel patient response outcomes have been developed to facilitate demonstration of efficacy and safety of drugs in development for OIC. © The American College of Gastroenterology 2011. All Rights Reserved.